

## Author index

### Volume 37 (1997)

- Aguilar Diosdado, M., see Rattarasarn, C. 37, 193  
Ambrosi, F., see Gregorio, F. 37, 21  
Anichini, R., see Seghieri, G. 37, 15  
Armstrong, D.G., see Lavery, L.A. 37, 41  
Ashry, H.R., see Lavery, L.A. 37, 41  
Ashwell, S., see Samaras, K. 37, 121
- Bacardi-Gascon, M., see Peña-Valdovinos, A. 37, 179  
Bache, I., K.H. Jørgensen, K. Buschard, Failure of high-dose insulin treatment to increase  $\beta$ -cell insulin content in diabetic non obese diabetic (NOD) mice 37, 9  
Bennardini, F., see Seghieri, G. 37, 15  
Berger, W., see Langewitz, W. 37, 157  
Bergström, A., see Wikblad, K. 37, 185  
Buschard, K., see Bache, I. 37, 9
- Campbell, L.V., see Samaras, K. 37, 121  
Casamitjana, R., see Rodríguez-Villar, C. 37, 145  
Chakrabarti, S., A.A.F. Sima, Endothelin-1 and endothelin-3-like immunoreactivity in the eyes of diabetic and non-diabetic BB/W rats. 37, 109  
Cheung, S.S.C., see Tze, W.J. 37, 149  
Chisholm, D.J., see Samaras, K. 37, 121  
Ciuti, M., see Seghieri, G. 37, 15  
Conget, I., see Rodríguez-Villar, C. 37, 145
- Deutsch, K., see Simmons, R.W. 37, 137  
Donnelly, R., L. Molyneaux, M. McGill, D.K. Yue, Detection and treatment of hypertension in patients with non-insulin-dependent diabetes mellitus: Does the 'rule of halves' apply to a diabetic population? 37, 35
- Filipponi, P., see Gregorio, F. 37, 21  
Fisher, E.J., see McAuliffe, A.V. 37, 101  
Fleury, A.C., see Samaras, K. 37, 121  
Franconi, F., see Seghieri, G. 37, 15
- Gironi, A., see Seghieri, G. 37, 15  
Gomis, R., see Rodríguez-Villar, C. 37, 145  
Gregorio, F., F. Ambrosi, S. Manfrini, A. Santucci, P. Filipponi, Metformin, plasma glucose and free fatty acids in type II diabetic out-patients: results of a clinical study 37, 21  
Gui, T., see Nishimura, C. 37, 173
- Harkless, L.B., see Lavery, L.A. 37, 41  
Hayakawa, M., see Nishimura, C. 37, 173  
Hotta, Y., see Nishimura, C. 37, 173
- Ichikawa, F., see Yuan, X. 37, 1  
Ihm, S.-H., see Park, S.-W. 37, 165  
Iseli, J., see Langewitz, W. 37, 157  
Ishikawa, T., see Nishimura, C. 37, 173  
Ishiyama, S., see Yuan, X. 37, 1  
Ishizawa, M., see Ishizuka, T. 37, 49  
Ishizuka, T., T. Nagashima, K. Kajita, M. Yamamoto, H. Wada, S. Itaya, K. Yamada, A. Miura, Y. Kanoh, M. Ishizawa, K. Yasuda, Acute effects of phorbol ester and insulin on insulin-induced glucose uptake and protein kinase C activation in rat adipocytes 37, 49  
Itaya, S., see Ishizuka, T. 37, 49
- Jiménez-Cruz, A., see Peña-Valdovinos, A. 37, 179  
Jørgensen, K.H., see Bache, I. 37, 9
- Kajita, K., see Ishizuka, T. 37, 49  
Kanai, A., see Nishimura, C. 37, 173  
Kanoh, Y., see Ishizuka, T. 37, 49  
Kessi, J., see Wikblad, K. 37, 185  
Koyama, K.-i., see Yuan, X. 37, 1  
Koyama, W., see Yuan, X. 37, 1  
Koyanagi, A., see Yuan, X. 37, 1
- Langewitz, W., B. Wössmer, J. Iseli, W. Berger, Psychological and metabolic improvement after an outpatient teaching program for functional intensified insulin therapy (FIT) 37, 157  
Lavery, L.A., W.H. van Houtum, D.G. Armstrong, L.B. Harkless, H.R. Ashry, S.C. Walker, Mortality following lower extremity amputation in minorities with diabetes mellitus 37, 41

- Lee, K.-U., see Park, S.-W. 37, 165  
 Leyva-Pacheco, R., see Peña-Valdovinos, A. 37, 179
- Mackintosh, A.-M., see Samaras, K. 37, 121  
 Manfrini, S., see Gregorio, F. 37, 21  
 Manzanares, J.M., see Rodríguez-Villar, C. 37, 145  
 McAuliffe, A.V., E.J. Fisher, S.V. McLennan, D.K. Yue, J.R. Turtle, High glucose inhibits effect of ascorbic acid on [<sup>35</sup>S] sulphate incorporation in mesangial cell and matrix proteoglycan 37, 101  
 McGill, M., see Donnelly, R. 37, 35  
 McLennan, S.V., see McAuliffe, A.V. 37, 101  
 Miura, A., see Ishizuka, T. 37, 49  
 Molyneaux, L., see Donnelly, R. 37, 35  
 Mugusi, F., see Wikblad, K. 37, 185
- Nagashima, T., see Ishizuka, T. 37, 49  
 Nawata, H., see Noda, K. 37, 129  
 Nishimura, C., Y. Hotta, T. Gui, A. Seko, Takuro Fujimaki, T. Ishikawa, M. Hayakawa, A. Kanai, T. Saito, The level of erythrocyte aldose reductase is associated with the severity of diabetic retinopathy 37, 173  
 Noda, K., F. Umeda, H. Nawata, Effect of acarbose on glucose intolerance in patients with non-insulin-dependent diabetes mellitus 37, 129  
 Nonaka, K., see Yuan, X. 37, 1
- Omura, S., see Takeuchi, F. 37, 81
- Park, J.Y., see Park, S.-W. 37, 165  
 Park, S.-W., S.-H. Ihm, H.J. Yoo, J.Y. Park, K.-U. Lee, Differential effects of ambient blood glucose level and degree of obesity on basal serum C-peptide level and the C-peptide response to glucose and glucagon in non-insulin-dependent diabetes mellitus 37, 165  
 Peña-Valdovinos, A., A. Jiménez-Cruz, R. Leyva-Pacheco, M. Bacardi-Gascon, Metabolic control in diabetic patients at the primary care level in México 37, 179
- Rattarasarn, C., M. Aguilar Diosdado, S. Soonthornpun, Glutamic acid decarboxylase antibodies in non-insulin-dependent diabetes patients with secondary sulfonylurea failure in Thailand 37, 193  
 Richardson, C., see Simmons, R.W. 37, 137  
 Rodríguez-Villar, C., I. Conget, R. Casamitjana, J. Vidal, J.M. Manzanares, R. Gomis, High proinsulin levels in late PRE-IDDM stage 37, 145  
 Roth, R.A., see Takeuchi, F. 37, 81
- Saito, T., see Nishimura, C. 37, 173  
 Samaras, K., S. Ashwell, A.-M. Mackintosh, A.C. Fleury, L.V. Campbell, D.J. Chisholm, Will older sedentary people with non-insulin-dependent diabetes mellitus start exercising?: A health promotion model 37, 121
- Santucci, A., see Gregorio, F. 37, 21  
 Sato, H., N. Shiina, Effect of an  $\alpha$ -glucosidase inhibitor on glomerular basement membrane anionic sites in streptozotocin induced mildly diabetic rats 37, 91  
 Seghieri, G., R. Anichini, M. Ciuti, A. Gironi, F. Bennardini, F. Franconi, Raised erythrocyte polyamine levels in non-insulin-dependent diabetes mellitus with great vessel disease and albuminuria 37, 15  
 Seko, A., see Nishimura, C. 37, 173  
 Seta, K.A., see Takeuchi, F. 37, 81  
 Shiina, N., see Sato, H. 37, 91  
 Sima, A.A.F., see Chakrabarti, S. 37, 109  
 Simmons, R.W., C. Richardson, K. Deutsch, Limited joint mobility of the ankle in diabetic patients with cutaneous sensory deficit 37, 137  
 Smide, B., see Wikblad, K. 37, 185  
 Soonthornpun, S., see Rattarasarn, C. 37, 193
- Tai, J., see Tze, W.J. 37, 149  
 Takeuchi, F., K.A. Seta, S. Omura, R.A. Roth, Insulin degradation by Madin-Darby canine kidney cells expressing the insulin receptor 37, 81  
 Takuro Fujimaki, see Nishimura, C. 37, 173  
 Turtle, J.R., see McAuliffe, A.V. 37, 101  
 Tze, W.J., J. Tai, S.S.C. Cheung, Prolongation of pig islet xenograft survival in rats immunosuppressed with FK506 37, 149
- Umeda, F., see Noda, K. 37, 129
- van Houtum, W.H., see Lavery, L.A. 37, 41  
 Vidal, J., see Rodríguez-Villar, C. 37, 145
- Wada, H., see Ishizuka, T. 37, 49  
 Walker, S.C., see Lavery, L.A. 37, 41  
 Wikblad, K., B. Smide, A. Bergström, J. Kessi, F. Mugusi, Outcome of clinical foot examination in relation to self-perceived health and glycaemic control in a group of urban Tanzanian diabetic patients 37, 185  
 Wössmer, B., see Langewitz, W. 37, 157
- Yamada, K., see Ishizuka, T. 37, 49  
 Yamada, K., see Yuan, X. 37, 1  
 Yamamoto, M., see Ishizuka, T. 37, 49  
 Yasuda, K., see Ishizuka, T. 37, 49  
 Yoo, H.J., see Park, S.-W. 37, 165  
 Yuan, X., K. Yamada, K.-i. Koyama, F. Ichikawa, S. Ishiyama, A. Koyanagi, W. Koyama, K. Nonaka,  $\beta_3$ -adren-  
 ergic receptor gene polymorphism is not a major genetic determinant of obesity and diabetes in Japanese general population 37, 1  
 Yue, D.K., see Donnelly, R. 37, 35  
 Yue, D.K., see McAuliffe, A.V. 37, 101

## Subject index

### Volume 37 (1997)

**Acarbose;** Non-insulin-dependent diabetes mellitus; Glucose tolerance; Principal component analysis; Insulin resistance 37, 129

**Adipocytes;** Insulin; Protein kinase C; Phorbol ester 37, 49

**$\beta_3$ -adrenergic receptor;** Obesity; Impaired glucose tolerance; Visceral fat 37, 1

**African-American;** Diabetes; Amputation; Mortality; Hispanic; Race 37, 41

**Albuminuria;** Polyamines; Non-insulin-dependent diabetes mellitus; Macroangiopathy 37, 15

**Amputation;** Diabetes; Mortality; African-American; Hispanic; Race 37, 41

**Angiopathy;** Diabetic foot; Neuropathy; Foot ulcer; Tanzania 37, 185

**Anionic sites;**  $\alpha$ -glucosidase inhibitor; Streptozotocin; Nephropathy; Urine albumin 37, 91

**Ankle;** Limited joint mobility; Flexibility; Diabetes; Cutaneous deficit 37, 137

**Anti-diabetic activity;** Metformin; FFA; Bed-time administration 37, 21

**Antihypertensive treatment;** Non-insulin-dependent diabetes mellitus; Hypertension; Blood pressure control 37, 35

**Ascorbic acid;** Glucose; Mesangial cells; Mesangium matrix; Proteoglycan 37, 101

**BB-rat;** Endothelin-1; Endothelin-3; Eye; Diabetes 37, 109

**Bed-time administration;** Metformin; FFA; Anti-diabetic activity 37, 21

**Blood glucose;** C-peptide; Non-insulin-dependent diabetes mellitus; Body mass index; Fasting serum glucose 37, 165

**Blood pressure control;** Non-insulin-dependent diabetes mellitus; Hypertension; Antihypertensive treatment 37, 35

**Body mass index;** Blood glucose; C-peptide; Non-insulin-dependent diabetes mellitus; Fasting serum glucose 37, 165

**$\beta$ -cells;** NOD-mice; IDDM; Insulin 37, 9

**C-peptide;** Blood glucose; Non-insulin-dependent diabetes mellitus; Body mass index; Fasting serum glucose 37, 165

**Cutaneous deficit;** Limited joint mobility; Flexibility; Diabetes; Ankle 37, 137

**Degradation;** Kidney; Insulin 37, 81

**Diabetes;** Amputation; Mortality; African-American; Hispanic; Race 37, 41

**Diabetes;** Endothelin-1; Endothelin-3; Eye; BB-rat 37, 109

**Diabetes;** Limited joint mobility; Flexibility; Cutaneous deficit; Ankle 37, 137

**Diabetes mellitus;** Metabolic control; Primary care level 37, 179

**Diabetic foot;** Neuropathy; Angiopathy; Foot ulcer; Tanzania 37, 185

**Diabetic retinopathy;** Erythrocyte aldose reductase; Risk factor; Non-insulin-dependent diabetes mellitus 37, 173

**Doctor-patient-relationship;** Intensified insulin therapy; Functional insulin therapy; Metabolic effects; Psychological effects; Quality of life 37, 157

**Endothelin-3;** Endothelin-1; Eye; BB-rat; Diabetes 37, 109



- Endothelin-1**; Endothelin-3; Eye; BB-rat; Diabetes 37, 109
- Erythrocyte aldose reductase**; Risk factor; Diabetic retinopathy; Non-insulin-dependent diabetes mellitus 37, 173
- Exercise initiation**; Older people; Health promotion; Glycaemic control; Lipids 37, 121
- Eye**; Endothelin-1; Endothelin-3; BB-rat; Diabetes 37, 109
- Fasting serum glucose**; Blood glucose; C-peptide; Non-insulin-dependent diabetes mellitus; Body mass index 37, 165
- FFA**; Metformin; Anti-diabetic activity; Bed-time administration 37, 21
- FK506**; Pig islets; Xenotransplantation; Rat; Immunohistochemistry 37, 149
- Flexibility**; Limited joint mobility; Diabetes; Cutaneous deficit; Ankle 37, 137
- Foot ulcer**; Diabetic foot; Neuropathy; Angiopathy; Tanzania 37, 185
- Functional insulin therapy**; Intensified insulin therapy; Metabolic effects; Psychological effects; Quality of life; Doctor-patient-relationship 37, 157
- Glucose**; Ascorbic acid; Mesangial cells; Mesangium matrix; Proteoglycan 37, 101
- Glucose tolerance**; Acarbose; Non-insulin-dependent diabetes mellitus; Principal component analysis; Insulin resistance 37, 129
- $\alpha$ -glucosidase inhibitor**; Streptozotocin; Nephropathy; Urine albumin; Anionic sites 37, 91
- Glutamic acid decarboxylase antibodies**; Non-insulin-dependent diabetes; Insulin-dependent diabetes 37, 193
- Glycaemic control**; Exercise initiation; Older people; Health promotion; Lipids 37, 121
- Health promotion**; Exercise initiation; Older people; Glycaemic control; Lipids 37, 121
- Hispanic**; Diabetes; Amputation; Mortality; African-American; Race 37, 41
- Hypertension**; Non-insulin-dependent diabetes mellitus; Blood pressure control; Antihypertensive treatment 37, 35
- IDDM**; NOD-mice; Insulin;  $\beta$ -cells 37, 9
- Immunohistochemistry**; Pig islets; Xenotransplantation; Rat; FK506 37, 149
- Impaired glucose tolerance**;  $\beta_3$ -adrenergic receptor; Obesity; Visceral fat 37, 1
- Insulin**; Adipocytes; Protein kinase C; Phorbol ester 37, 49
- Insulin**; Degradation; Kidney 37, 81
- Insulin-dependent diabetes**; Glutamic acid decarboxylase antibodies; Non-insulin-dependent diabetes 37, 193
- Insulin**; NOD-mice; IDDM;  $\beta$ -cells 37, 9
- Insulin resistance**; Acarbose; Non-insulin-dependent diabetes mellitus; Glucose tolerance; Principal component analysis 37, 129
- Insulin**; Type 1 prediabetes; Proinsulin 37, 145
- Intensified insulin therapy**; Functional insulin therapy; Metabolic effects; Psychological effects; Quality of life; Doctor-patient-relationship 37, 157
- Kidney**; Degradation; Insulin 37, 81
- Limited joint mobility**; Flexibility; Diabetes; Cutaneous deficit; Ankle 37, 137
- Lipids**; Exercise initiation; Older people; Health promotion; Glycaemic control 37, 121
- Macroangiopathy**; Polyamines; Non-insulin-dependent diabetes mellitus; Albuminuria 37, 15
- Mesangial cells**; Ascorbic acid; Glucose; Mesangium matrix; Proteoglycan 37, 101
- Mesangium matrix**; Ascorbic acid; Glucose; Mesangial cells; Proteoglycan 37, 101
- Metabolic control**; Diabetes mellitus; Primary care level 37, 179
- Metabolic effects**; Intensified insulin therapy; Functional insulin therapy; Psychological effects; Quality of life; Doctor-patient-relationship 37, 157
- Metformin**; FFA; Anti-diabetic activity; Bed-time administration 37, 21
- Mortality**; Diabetes; Amputation; African-American; Hispanic; Race 37, 41
- Nephropathy**;  $\alpha$ -glucosidase inhibitor; Streptozotocin; Urine albumin; Anionic sites 37, 91
- Neuropathy**; Diabetic foot; Angiopathy; Foot ulcer; Tanzania 37, 185

- NOD-mice; IDDM; Insulin;  $\beta$ -cells** 37, 9
- Non-insulin-dependent diabetes; Glutamic acid decarboxylase antibodies; Insulin-dependent diabetes** 37, 193
- Non-insulin-dependent diabetes mellitus; Acarbose; Glucose tolerance; Principal component analysis; Insulin resistance** 37, 129
- Non-insulin-dependent diabetes mellitus; Blood glucose; C-peptide; Body mass index; Fasting serum glucose** 37, 165
- Non-insulin-dependent diabetes mellitus; Erythrocyte aldose reductase; Risk factor; Diabetic retinopathy** 37, 173
- Non-insulin-dependent diabetes mellitus; Hypertension; Blood pressure control; Antihypertensive treatment** 37, 35
- Non-insulin-dependent diabetes mellitus; Polyamines; Macroangiopathy; Albuminuria** 37, 15
- Obesity;  $\beta_3$ -adrenergic receptor; Impaired glucose tolerance; Visceral fat** 37, 1
- Older people; Exercise initiation; Health promotion; Glycaemic control; Lipids** 37, 121
- Phorbol ester; Adipocytes; Insulin; Protein kinase C** 37, 49
- Pig islets; Xenotransplantation; Rat; FK506; Immunohistochemistry** 37, 149
- Polyamines; Non-insulin-dependent diabetes mellitus; Macroangiopathy; Albuminuria** 37, 15
- Primary care level; Diabetes mellitus; Metabolic control** 37, 179
- Principal component analysis; Acarbose; Non-insulin-dependent diabetes mellitus; Glucose tolerance; Insulin resistance** 37, 129
- Proinsulin; Type 1 prediabetes; Insulin** 37, 145
- Protein kinase C; Adipocytes; Insulin; Phorbol ester** 37, 49
- Proteoglycan; Ascorbic acid; Glucose; Mesangial cells; Mesangium matrix** 37, 101
- Psychological effects; Intensified insulin therapy; Functional insulin therapy; Metabolic effects; Quality of life; Doctor-patient-relationship** 37, 157
- Quality of life; Intensified insulin therapy; Functional insulin therapy; Metabolic effects; Psychological effects; Doctor-patient-relationship** 37, 157
- Race; Diabetes; Amputation; Mortality; African-American; Hispanic** 37, 41
- Rat; Pig islets; Xenotransplantation; FK506; Immunohistochemistry** 37, 149
- Risk factor; Erythrocyte aldose reductase; Diabetic retinopathy; Non-insulin-dependent diabetes mellitus** 37, 173
- Streptozotocin;  $\alpha$ -glucosidase inhibitor; Nephropathy; Urine albumin; Anionic sites** 37, 91
- Tanzania; Diabetic foot; Neuropathy; Angiopathy; Foot ulcer** 37, 185
- Type 1 prediabetes; Insulin; Proinsulin** 37, 145
- Urine albumin;  $\alpha$ -glucosidase inhibitor; Streptozotocin; Nephropathy; Anionic sites** 37, 91
- Visceral fat;  $\beta_3$ -adrenergic receptor; Obesity; Impaired glucose tolerance** 37, 1
- Xenotransplantation; Pig islets; Rat; FK506; Immunohistochemistry** 37, 149

